INNOVATION MODELS IN THE BIOPHARMACEUTICAL SECTOR - Innovation in the Biopharmaceutical Industry - page 29

Scherer, FM (2004). The pharmaceutical industry — prices and progress. New England
Journal of Medicine , 351(9), 927-932.
Schmookler, J (1966). Invention and Economic Growth . Harvard University Press.
Schumpeter, JA (1934). The Theory of Economic Development . Harvard University Press.
Schumpeter, JA (1963). Capitalism, Socialism and Democracy .NewYork:Harper&Low.
Schumpeter, JA (1939). Business Cycles . New York: McGraw Hill.
Schoffski, O (2002). Diffusion of Medicines in Europe . Burgdorf, Germany: Health Eco-
nomics Research Centre.
Schweitzer, SO (1997). Pharmaceutical Economics and Policy . Oxford: Oxford University
Press.
Sharp, ML (1999). Pharmaceuticals and biotechnology. In Perspectives for the European
Industry in Technology , C Freeman, M Sharp and W Walker (eds.).
Sharp, ML (1999). The science of nations: European multinationals and American biotech-
nology. International Journal of Biotechnology , 1, 132.
Stalk, G (1988). Time — the next source of competitive advantage. Harvard Business
Review , July, 41.
Thomas, L (1994). Implicit industrial policy: the triumph of Britain and the failure of France
in global pharmaceuticals. Industrial and Corporate Change , 3, 451-489.
Tidd J (2006). Innovation Models, Discussion Paper . London: Tanaka Business School,
Imperial College.
Tidd, J, J Bessant and K Pavitt (2005). Managing Innovation: Integrating Technological,
Market and Organizational Change , 3rd Edn. Wiley.
Tushman, M and P Anderson (1987). Technological discontinuities and organizational envi-
ronments. Administrative Science Quarterly , 31(3), 439-465.
US General Accounting Office Report (1994). Prescription drugs: spending controls in four
European countries. GAO/HEHS-94-30.
Utterback, J (1994). Mastering the Dynamics of Innovation , p. 256. Boston, MA: Harvard
Business School Press.
Utterback, J and HJ Acee (2005). Disruptive technologies: an expanded view. International
Journal of Innovation Management , 9(1), 1-18.
Walley, T, P Folino-Gallo, U Schwabe and E van Ganse (2004). Variations and increase
in the use of statins in Europe: data from administrative databases. British Medical
Journal , 328, 385-386.
Wells, N (1988). Innovative Chemical Extensions—The Economic Basis of Pharmaceutical
Progress . London: OHE (Monograph).
Zucker, LG and MR Darby (1997). Present at the biotechnological revolution: transfor-
mation of technological identity for a large incumbent pharmaceutical firm. Research
Policy , 26, 429.